Atropos Health Announces AI-Driven Commercial Analytics Solution for Life Science Companies

Audio By Carbonatix

PALO ALTO, Calif.--(BUSINESS WIRE)--Jan 12, 2026--

Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence (RWE), today announced the availability of Commercial Analytics solutions for life science leaders. This is an extension to the already growing number of solutions available to life science companies to accelerate decision making across the Real World Data, R&D, HEOR/Medical, and Brand use cases.

The solution leverages the speed and accuracy of ChatRWD® to generate rapid answers while transparently displaying actionable insights. Commercial and brand leaders generate high-quality, brand-specific insights delivered in seconds with not only the visuals they need - but also the data behind the dashboards.

"The Commercial Analytics solution is a natural progression from our solutions for RWE and Precision Medicine," said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “Building off our clinical grade quality and accuracy, we are expanding the type of questions and use cases biopharma users can ask and making available our ever-expanding Atropos Evidence™ Network to ensure the right data is being used for every analysis."

For this new solution, supported use cases include, but are not limited to, market sizing & segmentation, prescription trends, HCP and account targeting, patient journey, switching behavior, market share, salesforce & omnichannel optimization and launch tracking & uptake analysis. Customers will benefit from reducing the time from question to answer by leveraging ChatRWD and GENEVA OS®, as well as a growing library of existing studies and analysis - now over 10M novel studies - further advancing the company’s AI solution growth and leveraging the Atropos Evidence Network data.

"With the basis of a product built upon point of care and clinical decision use cases, we are able to now extend the use of RWD to more applications that can reduce the time from symptom to treatment," said Neil Sanghavi, President and Head of Product at Atropos Health. "Commercial and Brand leaders require high quality data to make decisions about where to deploy resources and the Atropos Health Commercial Analytics solution provides faster access to data to inform those decisions."

This product release comes on the heels of Atropos Health announcing the integration of the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform and presenting rare disease AI algorithms at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition last year.

To learn more about the Commercial Analytics solution, watch this video.

About Atropos Health

Atropos Health is the developer of GENEVA OS®, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improve individual patient outcomes with data-driven care, and expedite research that advances the field of medicine. We aim to transform healthcare with timely, relevant, real-world evidence.

To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or X (Twitter).

View source version on businesswire.com:https://www.businesswire.com/news/home/20260112967499/en/

CONTACT: Media Contact:

SolComms

Evan Scarduffa

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: RESEARCH TECHNOLOGY HEALTH TECHNOLOGY SOFTWARE PHARMACEUTICAL HEALTH DATA MANAGEMENT SCIENCE ARTIFICIAL INTELLIGENCE OTHER SCIENCE

SOURCE: Atropos Health

Copyright Business Wire 2026.

PUB: 01/12/2026 09:00 AM/DISC: 01/12/2026 09:03 AM

http://www.businesswire.com/news/home/20260112967499/en